Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Patient characteristics

From: Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis

Lead author (year) Country of conduct and year Age category Mean age (SD) in years M/F, % Sample size
Vaccine Placebo
Leibovitz (1971) [24] USA, 1970 Adults NR NR 1,682 7,934
Beutner (1979) [25] USA, 1974 Children Range: 7 to 14 50/50 520 460
Rytel (1977) [26] USA, 1974 Adults NR 0/100 95 48
Monto (1982) [27] USA, 1979 Adults NR NR 144 140
Tannock (1984) [28] Australia, 1981 Adults 34.8 (13.9) 69/31 19 20
Keitel (1997) [29] USA, 1983 to 1988 Adults Range: 30 to 60 NR Y1: 161 Y1: 298
Y2: 172 Y2: 241
Y3: 153 Y3: 253
Y4: 203 Y4: 217
Y5: 121 Y5: 145
Gruber (1990) [30] USA, 1985 Children 7.9 (3.3) NR 54 77
Edwards (1994) [31] USA, 1986 to 1990 Adults/Children Range: 1 to 65 NR LAIV/TIV  
Y1: 872/878 Y1: 878
Y2: 1,029/1,060 Y2: 1,064
Y3: 1,114/1,126 Y3: 1,125
Y4: 999/1,016 Y4: 1,016
Clover (1991) [32] USA, 1989 Children 8.8 (3.6) NR TIV/BIV 54/56 82
Govaert (1994) [33] The Netherlands, 1991 Older patients Range: 60 to 91 47/53 927 911
Powers (1995) [34] USA, 1993 Adults Range: 18 to 45 NR TIV/other 26/26 24
Belshe (1998) [35] USA, 1996 Children 3.5 (1.4) 47/53 1,070 532
Rudenko (2001) [36] Russia, 1996 Older patients Median: 73, Range: 41 to 95 30/70 LAIV/TIV 111/93 109
Belshe (2000) [37] USA, 1997 Children 4.5 (1.4) 52/48 917 441
Bridges (2000) [38] USA, 1997 to 1999 Adults Median: 43.5 78/22 Y1: 138 Y1: 137
Y2: 141 Y2: 137
Hoberman (2003) [39] USA, 1999 to 2001 Children Range: 0.5 to 2 56/44 Y1: 273 Y1: 138
Y2: 252 Y2: 123
Tam (2007) [40] Multisite trial in Asia, 2000 to 2002 Children 1.9 (0.6) 53/47 Y1: 1,653 Y1: 1,111
Y2: 503 Y2: 494
Vesikari (2006) [41] Multisite trial in Europe and Israel, 2000 to 2001 Children 2.0 (0.7) 51/49 Y1: 951 Y1: 665
Y2: 640 Y2: 450
Bracco Neto (2009)a[10] Multisite trial in South Africa and South America, 2001 to 2002 Children Range: 0.5 to 3 49/51 Y1: 944 Y1: 942
Y2: 338 Y2: 342
Forrest (2008) [42] Multisite in Asia, 2002 Children 1.8 Range: 0.5 to 3 NR 525 516
Lum (2010) [43] Multisite trial in Asia, Europe and South America, 2002 Children 1.2 (0.3) 50/50 765 385
Langley (2011) [44] Canada, 2003 Adults 37.1 (12.2) 46/54 455 443
Ohmit (2006)a[11] USA, 2004 Adult 26.9 (9.3) 38/62 LAIV/TIV 519/522 206
Treanor (2007)a[12] USA, 2004 Adults Median: 31, Range: 18 to 49 37/63 151 153
Beran (2009) [45] Czech Republic, 2005 Adults 35 (13) 45/55 4,137 2,066
Jackson (2010) [15] USA, 2005 Adults 32.7 (9.1) 40/60 Y1: 1,706 Y1: 1,725
Y2: 2,011 Y2: 2,043
Ohmit (2008)a[13] USA, 2005 Adults 24.9 (NR) 40/60 LAIV/TIV 853/867 338
Beran (2009) [46] Multisite trial Europe, 2006 Adults 40.0 (13.3) 40/60 5,103 2,549
Monto (2009)a[14] USA, 2007 Adults 23.3 (7.4) 38/62 LAIV/TIV 813/814 325
Frey (2010) [47] Multisite trial North America and Europe, 2007 Adults 32.5 (NR) 44/45 LAIV/TIV 3,776/3,638 3,843
Range: 18 to 48
Treanor (2011) [48] USA, 2007 Adults 32.5(NR) 41/59 2,344 2,304
Range: 18 to 55
Barrett (2011) [49] Multisite trial in USA, 2008 Children Range: 18 to 49 NR 3,619 3,617
Cowling (2010) [50] Hong Kong, 2008 Children Range: 6 to 15 53/47 71 48
Talaat (2010) [51] USA, 2009 Adults and older patients 56.5 (18.0) 43/57 389 97
  1. aUnpublished data was obtained from the author(s).
  2. LAIV live attenuated influenza vaccine, NR not reported, TIV trivalent inactivated vaccine.